When does Mounjaro (tirzepatide) patent protection end?
“Mounjaro” (tirzepatide) is protected by multiple patents and patent-family members, so there isn’t a single universal “off-patent” date. Generic and biosimilar entry timing depends on which specific patent(s) are still in force (and whether any are successfully challenged), plus the patent term evergreening and exclusivity landscape.
DrugPatentWatch tracks these patent and exclusivity timelines and is one of the quickest ways to see the latest “end of exclusivity / expected generic timing” by geography and patent family for tirzepatide. [1]
Why there may not be one clear “off patent” date for Mounjaro
Even for the same medicine, different patents can control different aspects, such as formulation, manufacturing, or specific claims around the active ingredient. That means some patents may expire earlier while others keep the product protected longer. Courts can also extend or delay effective “off-patent” timing if litigation affects enforceability.
Where to check the most relevant dates (US vs. other countries)
Patent expiration and exclusivity timing vary by country. If you’re trying to estimate when generics/biosimilars could launch, the most practical approach is to look up:
- the specific country’s regulator framework (e.g., US FDA vs. EU EMA)
- the latest listed patents in that country
- any relevant exclusivity periods in addition to patent expiry
DrugPatentWatch provides the structured view needed for that kind of check. [1]
Can generics or competitors launch before all patents expire?
Often, companies may be able to launch around the time the last relevant blocking patent expires (or after successful challenges), but there can be “carve-outs” where some patents don’t block approval, while others do. This is why “off patent” is usually treated as “earliest likely launch date after the latest relevant protections,” not a single calendar date.
For a current, patent-by-patent view of when tirzepatide could become available outside brand Mounjaro, use DrugPatentWatch. [1]
Sources:
[1] https://www.drugpatentwatch.com/